<DOC>
	<DOCNO>NCT02584283</DOCNO>
	<brief_summary>Rationale : Recent publication report good result control donation circulatory death ( DCD ) Maastricht category III liver transplantation strict donor-recipient matching apply ischemia time keep minimum . However major concern remain high rate biliary complication transplantation DCD liver . Non-anastomotic biliary stricture ( NAS ) occur 29 % patient receive DCD graft whereas incidence NAS recipient donation brain death ( DBD ) liver graft 11 % . NAS associate high morbidity increase cost liver transplantation . Injury biliary epithelium peribiliary vascular plexus occur donor warm ischemia static cold storage ( SCS ) identify major risk factor development NAS . Machine perfusion propose alternative strategy organ preservation , offer opportunity improve quality organ provide oxygen graft . Experimental study show end-ischemic dual hypothermic oxygenate machine perfusion ( DHOPE ) help liver graft recover ischemia restore mitochondrial function . Moreover , DHOPE show provide good preservation peribiliary vascular plexus bile duct , could important step forward reduce incidence NAS transplantation . Objective : To study efficacy end-ischemic DHOPE reduce incidence NAS within six month control DCD ( Maastricht category III ) liver transplantation . Study design : An international , multicenter , prospective , randomize , control , interventional , clinical trial two parallel arm approach ( treatment/control ) . Study population : Adult patient ( ≥18 yrs old ) undergo liver transplantation liver graft procure control DCD donor ( Maastricht category III ) body weight ≥40 kg . Intervention : In intervention group liver graft subject two hour hypothermic , oxygenated perfusion end SCS implantation . In control group donor liver graft preserve accordance standard practice SCS . Main study parameters/endpoints : The incidence severity symptomatic NAS diagnose Adjudication committee ( blind group assignment ) mean magnetic resonance cholangiopancreatography ( MRCP ) .</brief_summary>
	<brief_title>Dual Hypothermic Oxygenated Perfusion DCD Liver Grafts Preventing Biliary Complications After Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<mesh_term>Biliary Tract Diseases</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Adult patient ( ≥ 18 year old ) Signed informed consent Willing able attend followup examination Donor liver graft control donation circulatory death ( Maastricht category III ) Donors body weight ≥40 kg Simultaneous participation another clinical trial might possibly influence trial Mental condition render subject incapable understand nature , scope consequence trial Listed liver transplantation due fulminant liver failure retransplantation primary nonfunction Recipient positive test HIV Donor positive HIV , Hepatitis B C Simultaneous transplantation another organ Patients contraindication MRCP ( i.e . pacemaker )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Donation Circulatory Death</keyword>
	<keyword>Machine Perfusion</keyword>
</DOC>